In Vivo Lentivirus-based Macrophage Reprogramming Services
The Importance of Macrophages
Macrophages are characterized by their phagocytic activity, antigen presentation abilities, and phenotypic flexibility, all of which are key features that contribute to their important role in innate immunity. Due to their widespread presence in the body, macrophages serve as a promising target for therapeutic interventions in the treatment of various disorders. Nowadays, more and more attention focuses on the genetic programming of macrophages, which brings light to the treatment of intractable diseases and the improvement of life quality.
Fig.1 Tumor-promoting and immunosuppressing roles of tumor-associated macrophages (TAMs).1
Lentivirus-based Modification: Inclusive! Steady! Safe!
-
Lentivirus (LV) vectors can achieve a wider range of tissue tropism and have a larger capacity for prospective gene transport (up to 15 kbp) by utilizing various viral envelopes.
-
Lentivirus is capable of infecting both dividing and non-dividing cells, and it can integrate itself into the host chromosome. As a result, the transcript is expressed steadily and continuously in LV vectors.
-
Deleting the nef, vif, vpr, and vpu genes from lentivirus vectors not only enhances vector safety but also allows for the cloning of larger inserts.
Fig.2 Lentivirus-based gene transfer.2
Our In Vivo Lentivirus-based Macrophage Reprogramming Services
As a pioneer in the tumor-immunity field, Creative Biolabs integrates lentivirus-based cell modification with macrophage reprogramming and successfully developed a series of in vivo lentivirus-based macrophage reprogramming services to assist the application of macrophage for disease treatment. We utilize the lentivirus vectors to deliver the desired gene into the macrophage for in vivo engineering purposes. Lentivirus-engineered macrophages not only enhance their activities but also maintain therapeutic gene expression for a prolonged duration. Throughout the process, we provide comprehensive customized services from lentivirus production to results visualization to meet global customers' diverse needs.
Term of different diseases and targets, we provide several related services and diverse target genes that can be chosen from for your projects:
Importantly, we also provide a lentivirus production service featuring strict quality control to deliver high-quality lentivirus productions for global customers.
Benefits of Our In Vivo Lentivirus-based Macrophage Reprogramming Services
Frequently Asked Questions
Q1: How about the lentivirus vector compared to another virus vector?
A1: The lentivirus may infect many different types of cells, including both dividing and non-dividing cells. It is particularly effective in infecting cells that are difficult to transfect, such as undifferentiated cells. Additionally, lentivirus is effective in cells that have a robust immune response against adenovirus infection. Lentivirus is capable of efficiently integrating foreign genes into the host chromosome and facilitating long-term and stable expression of the desired gene. Furthermore, lentivirus can be utilized not only in in vitro experiments but also in vivo animal models, particularly in animal tumorigenesis experiments.
Q2: What are the distinctions between in vivo and ex vivo cell therapy?
A2: Both in vivo and ex vivo approaches are often used for performing gene therapy. Compared to ex vivo cell treatment, the in vivo approach is superior in terms of accuracy and efficacy.
Work with Creative Biolabs
As a pioneer in the field, Creative Biolabs is committed to innovating technologies to aid in the development of disease treatment and improve human life quality. Here we provide an inquiry mode for your convenience to contact us. We are glad to receive your inquiry to know more about in vivo lentivirus-based macrophage reprogramming services.
References
-
Mantovani, Alberto, et al. "Macrophages as tools and targets in cancer therapy." Nature reviews. Drug discovery 21.11 (2022): 799-820.
-
Dissen, G.A. et al. Using Lentiviral Vectors as Delivery Vehicles for Gene Therapy. In: Morozov, A. (eds) Controlled Genetic Manipulations. Humana Press, Totowa, NJ 65 (2012): 69-96.
